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ABSTRACT 
 
The prospering wound healing treatment is one that minimizes the formation of connective 
tissue and reduces scar that is produced during healing process. Scar formation in healing can 
be reduced by blocking the prominent pathway responsible for it. Previous studies identify 
TGF-β as the major player in the pathways that lead to scar formation and thus can be 
targeted for exploring Antifibrotic drugs. The objective of the current study is to search and 
validate an effective inhibitor of TGF-β receptor to prevent scar formation during wound 
healing by utilizing the computational methods. Briefly, a group of newly discovered 
molecules from Drug Bank and other natural compounds predicted to act in TGF β pathway 
were selected to check their inhibitory activity against TGF-β1 receptor.  The ligands were 
docked against the active site of TGF-βR1 in Autodock4. A natural compound, Epicatechin 
Gallate showed highest binding energy (-9.44 kcal/mol) compared to the control, SB505124 
(-9.18 kcal/mol). Since previous studies have confirmed that Epicatechin Gallate is only 
effective in minor scars, design of an effective inhibitor for extensive scar was attempted by 
modifying the parent structure of Epicatechin Gallate. A series of ligands thus obtained 
exhibited better binding energy upon docking. Two such derived ligands showed a binding 
energy above -10.4kcal/mol. However, one of these derived ligands with added 
hydrophobicity at C5 position qualified for Drug likeness, Toxicity and ADME properties in 
PreADMET server. The same ligand also made a stable complex with the target as obtained 
in terms of RMSD and Total Energy measures by real time Molecular Dynamic Simulation 
studies. All the studies indicate S1 can act as effective inhibitor of TGF-β pathway. But 
further clinical trials were necessary to confirm its action. 
 Key Words: TGF-β, Drug bank, Docking, Molecular Dynamic Simulation, ADME,      
PreADMET, RMSD, Autodock. 
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2. INTRODUCTION 
 2.1 Wound 
A wound occurs when the wholeness of any tissue is negotiated. A wound may be induced as 
a result of a cut or  by an infectious disease; [1]. 
2.2 Types of wound  
Acute wounds are categorised in to these many types by emergency personnel and first aid 
workers.  
1. Abrasions (scrapes) – skin scratched away due to frictional force. 
2. Avulsions – constrained removal of tissue from body. 
3. Lacerations – blunt and irregular breaks due to use of high force.  
4. Punctures – narrow and deep wound due to penetration of sharp objects like a pin. 
5. Incisions – sharp cut due to sharp instrument. 
6. Contusions – internal injury due to forced trauma. 
 
2.3 Wound healing  
Wound healing, or wound repair, is an intricate process in which the skin repairs itself after 
injury.  The successful wound treatment  is one that reduces the formation of scar tissue and 
decreases the amount of necrotic tissue that is produced during this process [2]. 
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2.3.1 Normal Wound-Healing Phases. 
The wound passes through 4 phases so as to impact a final repair 
1) Barrier protection 
2) Inflammatory phase, 
3) Fibro plastic phase and 
4) Remodelling phase. 
2.3.1.1 The physical barrier  
Unless preventive measures are taken wounds will readily acquire bacteria. Established 
absorbent cellulose affords limited protection against bacteria, particularly in the presence of 
serous exudate that may negotiate dressing integrity. In addition, particles remaining in 
wound are shed by dressings. Many advanced dressings are impermeable to bacteria, are 
removed completely, and have been found to reduce the incidence of wound sepsis and 
optimize re epithelialization rates. 
2.3.1.2 The inflammatory phase  
The inflammatory phase sets up the area for healing and traps the wound by causing it to 
swell and develop pain, so that restricting the movement. The fibroplastic phase reconstructs 
the structure, and then final form is produced by remodelling phase. Inflammation is a 
essential prerequisite to healing.   
2.3.1.3 Fibroblastic Phase   
Rebuilding can commence after completion of inflammatory phase. It is named for the 
principal cell of scar production - the fibroblast. There are fewer types of cells operate and 
finishes about three weeks. During this phase the wound is resurfaced and passed on with 
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strength. The fibroblasts are originated from mesenchymal cells which are located in loose 
tissue around blood vessels and fat.  
2.3.1.4 Remodelling Phase  
Epithelialisation.   
Blood flow, phagocytosis, are the ingredients critical to tissue persistence, and the provision 
of a surface covering happen early in the healing process. The preparation of even a one-cell 
layer will furnish protection from external invading organisms. Within hours after injury, 
undamaged epithelial cells begin to reproduce. Epithelial mitosis is regeneration process 
which leads to a ridge forming around the periphery of the wound. 
Wound contraction.   
Epithelialisation closes wound surface, but contraction pulls the entire wound together in 
effect quenching the defect. A effective contraction results in a smaller wound to be repaired 
by scar formation.  Decreasing the area to be healed is truly beneficial in certain tissues with 
fixed, deep structures covered by mobile, loose skin.  
Collagen production.   
Wound healing is terminated by collagen production which is essential if wound healing is to 
occur. Collagen is synthesised by the migratory fibroblasts present throughout the wound. 
Collagen produced is influenced by development of lactic acid.  
Collagen fibre orientation   
Scar tissue is haphazardly deposited in remodelling phase to be arranged, in both lateral and 
linear orientation. Scar tissue being non-flexible and tries to mimic the characteristics of the 
tissue in which it is healing. Collagen weave is induced by tissue structure, thus dense tissues 
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induce highly cross-linked scar; pliable tissues induce a loose, coiled, less cross-linked scar. 
This  process does not function as expected  and results in unwanted scar tissue in the form of 
hypertrophic or keloid scars[1, 2].   
 
 
 
Figure1. Phases of wound healing for, Haemostasis (a), Inflammatory (b 
Proliferative(c), Remodelling (d) 
 
2.4 SCAR FORMATION 
Cutaneous wound healing is   a   complicated   process, which involves many different 
aspects including   growth factors, extracellular matrices and various cell types [3]. This 
healing process in adult human being or adult animals of higher vertebrate is usually 
overactive and can cause scar formation. Scarring is an unpleasant lesion to patients 
physically and psychologically. Sometimes, it also causes functional disability in severe burn 
patients. Keloid is an example of aberrant scarring in human being, which usually extends 
beyond the boundary of an original wound and is difficult to treat clinically.  Fortunately, the 
scar less wound healing process in fetal wound repair may provide insights into   the potential   
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conversion   of   adult wound healing into a healing process similar to that of fetal scar-free 
wound. The development of gene therapy techniques offers a powerful tool to genetically 
modify the healing process of adult wounds to a repair process similar to fetal wounds. 
Because  of  the  close   relationship   between  sustained expression of transforming growth 
factor- β  (TGF- β ) and the formation  of  keloid  and  hypertrophic  scar as well as transient, 
lower level expression of TGF- β  in fetal scar less wound healing this article intends to 
review the roles of TGF- β  in scar formation, the strategies of antagonizing wound TGF- β  
and preliminary results of scar gene therapy by targeting wound TGF- β . 
2.5 Mechanisms of TGFβ- Signalling from Cell Membrane to the Nucleus 
 
TGFβ is initiated  by type I and type II receptor serine/theorine kinases on the cell surface. 
Phosphorylation of type II receptor propagates signal through phosphorylation of Smad 
proteins. Type I receptor activates Co-mediator Smad (Co-Smad), the receptor-regulated 
Smad (R-Smad), and the inhibitory Smad (I-Smad). R-Smads (Smad1, 2, 3, 5, and 8) by 
direct phosphorylated undergo homotrimerization and formation of heteromeric complexes 
with the CoSmad, Smad4 , R-Smad. Which are translocated into the nucleus along with co 
factors and regulate the transcription of target genes. The I-Smad, Smad6 and Smad7, 
negatively regulate TGFβ- signaling by engaging with R-Smads for receptor or Co-Smad 
interaction and by targeting the receptors for degradation[4]. 
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Figure 2 - Schematic Diagram of TGF-β Signaling from Cell Membrane to the 
Nucleus[4] 
2.5.1 TGF-β Ligands and Receptors 
The TGFβ- family of cytokines, , are encoded by 42 open reading frames in human, 9 in fly, 
and 6 in worm characterized by six conserved cysteine residues [5]. The ligands dimeric 
arrangement suggests the formation of a complex with two type I and two type II receptors. 
Family of proteins collectively known as Ligand traps regulate the ligand access to the 
receptor. The receptor serine/threonine kinase family comprises 12 members—7 type I and 5 
type II receptors—all dedicated to TGFβ- signalling in human genome [6]. Both types of the 
receptor serine/threonine kinases consist of about 500 amino acids, organized sequentially 
into an N-terminal extra-cellular ligand binding domain, a transmembrane region, and a C-
terminal serine/threonine kinase domain. Three-finger toxin fold is exhibited by the overall 
structures of the extracellular ligand binding domain of the type I BMP receptor [7] as well as 
the type II receptors for Activin [8] and TGFβ [9], with each finger formed by a pair of anti-
parallel strands. 
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Figure 3 - A Formal Relationship Depicting TGF-β Ligands, , Type I and II Receptors 
,Accessory Receptors, Ligand Binding Traps  in Vertebrates[4] 
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3. OBJECTIVE 
 To explore the agents that are linked to TGF-β and it’s receptors,  central to 
transduction pathways responsible for scar formation 
 To identify a best drug amongst existing drug bank inhibitors of TGF-βR1 by binding 
energy estimation from ligand-protein docking  
 To design synthetic drugs from the best inhibitor by structural modification in Marvin 
Sketch. 
 To analyze the suitability of the novel inhibitors as drugs in Pre ADMET server. 
 To validate the stability of ligand-protein complexes by Molecular Dynamics 
Simulation studies. 
  
4. LITERATURE REVIEW 
4.1 TGFβ AND WOUND SCARRING 
In contrast to fetal wounds, enhanced expression of TGFβ and its receptors has been observed 
in hypertrophic scar and keloids. The hypertrophic scar fibroblasts   expressed TGF- β1 
mRNA in a level significantly higher than that of the normal fibroblasts. Schmid  et al. found  
TGF- β  receptors I and II  expressing more  in granulations tissue than  in  the  normal  skin   
at  both mRNA and protein levels[10]. Similarly, Lee  et al. have shown in an  in vitro study 
that  keloid   fibroblasts  produced  more   TGF- β1   and   TGF- β2 protein, but not TGF- β3, 
than normal fibroblast[11]. Chin  et al. further demonstrated an increased protein expression 
of TGF- β  receptors I and II in the cultured keloid fibroblasts as compared with the normal 
dermal fibroblasts[12]. These results suggest that overexpressed TGF- β ligands and their 
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receptors are associated with scar and keloid formation. Hence by targeting wound TGFβ  
wound scarring can be significantly reduced[13]. 
4.2 CELLULAR AND MOLECULAR MECHANISMS OF TGF-β IN 
SCAR FORMATION 
Although   the  mechanism  of  scar  formation  involves many different aspects and is too 
complicated , a number of studies have shown that TGF- β  plays a key role in scar formation 
via different mechanisms such as inflammation,  matrix  production,  matrix  remodeling,  
and the   regulation   of   cell   proliferation   and   apoptosis,   etc. During wounding, the 
initial dose of TGF- β appears to be an important factor to trigger the later cascade of TGF- β 
overproduction and scar formation. When a wound is created, TGF- β released from the 
platelets can recruit monocytes and other cells into the wound, and these cells further produce 
more TGF- β in the wound. Additionally, the initial dose of TGF- β in the early wound 
induces fibroblasts, the key player of scar formation, to produce their own TGF- β  in the 
later stage   wound   via   autocrine   regulation,   leading   to   the overproduction  of  wound  
TGF- β    and  eventually  to   scar formation . In vitro studies have shown that TGF- β 1 
promoted cell proliferation and  collagen  production  of both keloid and normal dermal 
fibroblast,  and  the  collagen  production stimulated by TGF- β  was mediated by Smad3 and 
Smad4 [14]. In vivo, overexpression of TGF- β1 gene has been observed at the peripheral 
area of keloid tissues, where highly proliferated cells reside. In addition, TGF-β1 gene 
expression is   also   co-localized to   the   area   where collagen gene is actively expressed; 
suggesting that TGF- β 1 produced   by    keloid    fibroblasts    also    promotes    their 
proliferation    and    collagen    production    in     the    local environment of keloid 
tissues.Wound tension is also known to promote scar formation. In an in vitro assay, Peled et 
al. have shown that mechanical strain could up-regulate the gene expression of TGF- β 1 and 
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its receptors as well as type I procollagen in normal dermal fibroblasts,   indicating   that 
enhanced expression of TGF- β 1 and its receptors by cellular strain may contribute to the 
tension-induced scarring 
4.3 STRATEGIES OF BLOCKING TGF- β BIOLOGICAL ROLES IN 
WOUNDS 
Wound scarring remains difficult to cure. Conventionally, scarring is considered as a natural 
result of wound healing and is inevitable. The study by Longaker et al. in a sheep model, 
however, demonstrated that the cleft lip defect of early gestational fetal sheep could be 
repaired without any scar formation[15]. This interesting phenomenon indicates that scar is 
not the necessary result of healing mammalian wounds, and adult wounds may be ideally 
repaired by tissue regeneration rather by fibrous tissue if their healing processes can be 
modified to mimic the mechanism of fetal scarless wound healing. A pioneer study by Shah 
et al. demonstrated for the first time  neutralizing wound TGF- β with anti-TGF- β antibodies 
in adult rodent[16]. This study provides direct evidence that manipulation of TGF- β effects 
in adult wounds is a good strategy of reducing wound scarring. Importantly, local 
manipulation of wound TGF- β can avoid the adverse effect of systemic manipulation of 
TGF- β, which may cause a lethal effect on experimented animals[17]. 
Manipulation of wound TGF- β at early stage is essential to the reduction of scarring, because 
the initial dose of TGF- β can trigger the cascade of TGF- β overproduction in wounds via its 
chemotaxis and autoinduction, which stimulates fibroblast proliferation and collagen 
production, inhibiting degradation of matrix and  leads to scar formation[18]. 
The second way of manipulating wound TGF- β effects at protein level is the use of TGF- β 
antagonists. Several different molecules are found to be able to bind TGF- β ligands and 
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block their biological effects. Decorin is a small chondroitin/dermatan sulfate proteoglycan 
[19]. The core protein fragment (Leu155-Val260) of decorin binds TGF- β[20] and inhibits 
TGF- β mediated biological effects[21, 22]. Border et al. injected decorin molecules 
intravenously and successfully inhibited the fibrotic process of glomerulonephritis, in which 
TGF- β also plays an important role in the pathogenesis[23]. Biglycan is another small 
proteoglycan that is able to bind TGF- β. Nevertheless, it may regulate TGF- β’s effect in 
vivo differentially from decorin[24]. Soluble forms of TGF- β receptors I and III (betaglycan) 
have been found in different cell types as a result of natural process of mRNA splicing[25, 
26]. Because the binding regions for TGF- β ligands are located at the extracellular domains, 
the soluble receptors remain able to bind their ligands but fail to signal intracellularly, and 
thus can serve as TGF- β antagonists. Since TGF- β receptor II initiates the ligand binding 
and the intracellular signaling, most studies used recombinant soluble TGF- β receptor II as 
an antagonist to neutralize various TGF- β effects[27-30].  
The third approach is to block TGF- β activation. Natural TGF- β is secreted as a biologically 
latent form, which can be activated by transient acidification, proteolysis, and chaotropic 
agents [Brown et al., 1990]. Since TGF- β can be activated via the binding of mannose-6-
phosphate (M6P) residues on LAP to the M6P receptors on cell surface[31], excessive M6P 
injected into wounds can compete with LAP and inhibit the activation of wound. TGF- β, and 
thus reduce scarring[32]. An antibody to LTBP or to transglutaminase and transglutaminase 
inhibitor may also inhibit the activation of latent TGF- β[33]. 
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4.4 Inhibitors of TGFβ pathway to reduce scar formation  
J-A Moon et al showed (TGFβ) plays a primarily role in the progression of renal fibrosis. IN-
1130, a new small molecule ALK5 inhibitor, inhibited the purified kinase domain of ALK5-
mediated Smad3 phosphorylation with an IC50 value of 5.3 and proved to be majorly 
selective in a panel of 27 serine/threonine and tyrosine kinases [34]. 
Anne-Charlotte de Gouville etal GW6604 (2-phenyl-4-(3-pyridin-2-yl-1H-pyrazol-4-yl) 
pyridine), an ALK5 inhibitor, to assess the therapeutic potential of inhibiting TGFβ pathway 
in different models of liver disease. GW6604 blocks TGFβ effects in vivo and inhibits TGFβ 
signaling in vitro [35]. 
 
Rudy Ciayadi etal synthesised novel inhibitors of TGFβ1 based on a 2-aryl-4-(3-(pyridin-2-
yl)-1H-pyrazol-4- yl) pyridine compounds containing phenyl or aromatic nitrogen 
heterocycle substituents. TGFβ1 is selectively inhibited in HEK-293T cells in culture [36].  
Hiroyuki Higashiyama etal SB-525334 treatment attenuated significantly decreased the type I 
and III procollagen and fibronectin mRNA expression in the lung [37]. Dominique Bonafoux 
etal The 4-(5-fluoro-6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-ylamine 3 is a 
powerful and selective inhibitor of TGFβR1. Replacement of the amino group of 3 typically 
led to a slight decrease in the affinity for the receptor and in TGFβ-inducted PAI-luciferase 
reporter activity. However, 2-acetamidoimidazole was attractive candidate for further 
optimization as a result of their significant activity combined to their superior 
pharmacokinetic profile [38]. 
Sunil K. Halder etal investigated the potential of TRKI in new therapeutic approaches in 
preclinical models. Transcription, gene expression, apoptosis, and growth suppression of 
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TGF-β is induced by TRKI, SB-431542.  SB-431542 was capable of rarefying TGFβ induced 
EMT the tumour-promoting effects of TGF-β, including  cell motility, migration and 
invasion, and vascular endothelial GFs secretion in human cancer cell lines[39]. 
Chul-Yong Park etal examined a new small molecule inhibitor of ALK5, 3-((5-[1, 2, 4] 
triazolo [1,5-a]pyridin-6-yl)-4-(6-methylpyridin-2-yl) thiazol-2ylamino) methyl) benzonitrile 
(EW-7203) in breast cancer cells to check if it has potential for cancer treatment. The 
inhibitory effects of EW-7203 on TGFβ-induced Smad signalling and epithelial to-
mesenchymal transition (EMT) were examinied in mammary epithelial cells using luciferase 
reporter assays, immunoblotting, and confocal microscopy and wound healing assays. The 
novel ALK5 inhibitor, EW-7203, expeditiously inhibited TGFβ1-induced Smad signalling 
[40]. 
Francüoise Gellibert etal identified a novel 1, 5-naphthyridine aminothiazole and pyrazole 
derivatives, has selective inhibitors of the transforming growth factor-â type I receptor, 
ALK5.  James F. Callahan, etal suggested that suppression of ALK5 by GW6604 (2-phenyl-
4-(3-pyridin-2-yl-1H-pyrazol-4-yl) pyridine), could be an appealing approach to treatment of 
liver fibrosis. Werner J[41]. Geldenhuys etal SB-505124 and  A83-01   binding  to the ATP 
Binding site of TGFβR1 and act as competitive inhibitors, and effective inhibition of TGFβ in 
cell culture[42] . 
N. J. LAPING, etal expressed the kinase domain of the TGF-β type I receptor [Activin 
receptor-like kinase (ALK) 5] and the substrate, Smad3, and determined that SB- 431542 is a 
selective inhibitor of Smad3 phosphorylation with an IC50 of 94 nM. It inhibited TGF-β 
induced nuclear Smad3 localization. The p38 mitogen-activated protein kinase inhibitors SB-
203580 and SB-202190 also inhibit phosphorylation of Smad3 by ALK5 with IC50 values of 
6 and 3M, respectively brotic diseases by both avoiding matrix deposition and promoting 
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hepatocyte regeneration[43]. Kai Fu, Michael J etal SM16 blocked TGFβ-induced 
plasminogen activator inhibitor (PAI) luciferase activity in cells, TGF-β and Activin-induced 
Smad2/3 phosphorylation [44]. 
 Stacey DaCosta Byfield etal In their study, characterized 2-(5βenzo [1,3]dioxol-5-yl-2-
tertβutyl-3Himidazol-4-yl)-6-methylpyridine hydrochloride (SB-505124 which suppress  the 
TGF-βR1 identified as ALK5. Reveal that this compound selectively and concentration-
dependently inhibits ALK4, ALK5, and ALK 7 dependent activation of downstream 
cytoplasmic signal transducers, but does not alter ALK1, ALK2, ALK3 or ALK6-induced 
Smad signaling[45]. 
Mohit Kapoor etal inquired scar formation reduction effect of the ECG, in a full thickness 
incisional pattern of wound healing in rats. Significant improvement in the quality of scar 
formation both in terms of development and orientation of the collagen fibres was shown by 
ECG . For the first time, their study revealed that catechins, namely ECG, can significantly 
improve the quality of wound healing and scar formation [46].  
Werner J.etal  Compounds such as SB-505124 and A83-01 have been shown to bind to the 
ATP Binding site of TGFβR1 and act as competitive inhibitors, and in cell culture have 
shown effective inhibition of TGFβ. Structurally, most of these compounds, which have been 
published, share a similar central core consisting of a pyrazole or imidazole with a 
pyridine[47]. 
Chul-Yong Park etal inquired a novel small molecule inhibitor of ALK5, (EW7203) in breast 
cancer cells to identify if it has potential for cancer treatment. The novel ALK5 inhibitor, 
EW-7203, inhibited the TGFβ1-stimulated transcriptional activation of p3TP-Lux and 
pCAGA12- Luc. The novel ALK5 inhibitor, EW-7203, efficiently inhibited TGFβ1-induced 
Smad signalling. 
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BINDING ENERGY ANALYSIS 
 
LIGAND-RECEPTOR INTERACTIONS USING 
LIGAND SCOUT AND LIGPLOT 
 
DESING OF NOVEL INHIBITOR AND COMPARING 
WITH EXISTING INHIBITORS 
PreADMET STUDIES OF BEST LIGANDS TO 
QUALIFY AS DRUG 
 
MOLECULAR DYNAMIC SIMULATION BY CHARMm 
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6. MATERIALS AND METHOD 
6.1 Tools used:  
 Marvin Sketch - For drawing Novel Ligand/Inhibitor  
 Online Translator - For Translating ligand file format to pdb  
 PDB - For Downloading Receptor/Protein .pdb files  
 Pubchem – Database of inhibitors 
 Prodrg Server- Energy minimization of  inhibitors 
 Chimera - For Visualization and Energy Minimization studies 
 Pymol – For visualization and alignment 
 Hex  - For  Automated Molecular Docking (protein +protein) 
 Auto Dock 4 - Potential offline Docking(protein+ligand) tool widely used  
 Ligand scout - To find the specific interactions 
 Lig plot – To find out  atomic interactions 
 PreADMET- To check drug likeness 
 CHARMm - Molecular dynamics simulation  
6.2 Retrieving receptors from pdb: 
 Open Protein data bank, pdb.org   
 Type receptor name in search i.e TGFβ receptor.   
 Retrieve the pdb files of the receptors and store them in pdb file format for further 
use.  
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Figure 4 - Snapshot of Protein Data Bank webpage with TGFβ1receptor 
 (PDB ID: 1VJY) 
 
6.3 Retrieving ligands from Pubchem and conversion to pdb format by 
Marvin sketch:  
 Open pubchem  pubchem.ncbi.nlm.nih.gov   
 In search type the name of inhibitor & enter   
 All the available ligands will appear, if something is missing search for the same in                       
chemspider.   
 Save the 3D .sdf format of the ligands from pubchem and chemspider.   
 Open the above .sdf format in Marvin sketch and save as .pdb    
 Now the pdb format ligand is in 3D structure that will be used in following steps.  
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Figure 5 - Snapshot of Marvin sketch (conversion to .pdb) 
6.4 Energy minimization of ligands:  
 
Before binding energy calculations are performed, it is necessary to correct structural 
inconsistencies, add hydrogen, and associate atoms with force field parameters. Energy 
minimization is used to compute the equilibrium configuration of ligand. It makes the ligand 
flexible so that ligand can properly orient itself on the receptor during docking. Energy 
minimization was done by PRODRG, an online server following the given steps-  
 Open Prodrg beta server.   
 Paste the pdb format of ligand in the space provided & run Prodrg.   
 Save the energy minimized pdb file (all hydrogens) generated by the server for future 
use.  
23 
 
 
Figure 6 - Snapshot of PRODRG server (online minimization page)  
6.5 Energy minimization of Receptor:  
The receptors obtained from the Protein Data Bank are generally complex files i.e., NMR 
structures of already docked receptor with some existing inhibitors. For using the same 
receptor for our docking studies, the receptor should be cleaned by eliminating the exiting 
ligand and the reactive groups created by removing this ligand should be substituted with 
hydrogens. For the removal of the ligands CHIMERA is used and from residue selecting 
option the Non amino acid groups can be selected and deleted. The resultant PDB structure 
can be saved. The following steps are followed-   
 Double click chimera open receptor file 
 Select all 
 Tools --Structure editing -- minimize structure 
 Choose the steps and  minimise 
 Save the resultant file in pdb format and use for docking 
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Figure 7 - Snapshot of CHIMERA  (Protein energy  minimization ) 
6.6 Docking Tools Autodock 4.0  
Docking is a method which predicts the preferred orientation of a small molecule (ligand) on 
a larger molecule (receptor) when bound to each other to form a stable complex. Each 
docking program utilizes a unique scoring function to rapidly approximate properties such as 
receptor-ligand binding. Here Autodock is used as the docking tool which uses free-energy 
scoring function that is based on a linear regression analysis and the AMBER force field that 
occur between a ligand and protein target 
The introduction of Autodock 4 comprises three major improvements:  
 The docking results are more accurate and reliable.  
 It can optionally model flexibility in the target macromolecule.  
 It enables AutoDock's use in evaluating protein-protein interactions.  
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AutoDock 4 offers many new features and improvements over previous versions. The most 
significant is that it models flexible side chains in the protein. We can get both the 3D 
structure and the inhibition constants. AutoDock4 scoring functions are van der Waals forces, 
Hydrogen Bonding, Electrostatics, Desolvation, Torsional.  
Binding energy=Intermolecular energy+ Torsional energy ΔGbind = ΔGvdw + ΔGele. + 
ΔGHβond + ΔG desolv +ΔGtors Here ΔG=change in free energy The aim of this part is to re-
dock the ligand present in the crystal structure of a protein using an automated docking suite 
called 'AutoDock'. The GUI for AutoDock is AutoDockTools (ADT), which was used to 
perform the entire docking task. More information is available on the AutoDock suite 
homepage http://www.scripps.edu/mb/olson/doc/autodock/.After preparing the protein and 
ligand files through chimera, all files must be transferred to the Autodock directory. Further 
modification to the protein and ligand, something like fixing the torsion residues etc are made 
and the files are saved in PDBQT format. The grid box is setted on the protein. After 
Autodock completes, the docking results are saved in a file named dlg in the directory. The 
conformation with the lowest docking energy is ranked best by AutoDock. One can see the 
clusters of docked conformations based on Binding energies by Opening and scrolling down 
the dlg file until we find 'CLUSTERING HISTOGRAM'. Make a note of the cluster rank, 
lowest docked energy, number of conformations in the cluster. 
AutoDock is used to perform computational molecular docking of small molecules to 
proteins, DNA, RNA and other important macromolecules, by treating the ligand and 
selected parts of the target as conformationally flexible. It uses a scoring function based on 
the AMBER force field, and estimates the free energy of binding of a ligand to its target. 
Novel hybrid global-local evolutionary algorithms are used to search the phase space of the 
ligand-macromolecule system.  
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The steps followed are as mentioned below-  
 
 Get the receptor (1VJY) coordinates (i.e., from the PDB).  
 Clean the receptor (delete all the water and all non-interacting ions).  
 Add the missing hydrogens/side chain atoms and minimize the receptor   
 Get the minimized ligand from PRODRG server  
 Prepare the docking suitable files for LOCK and KEY (pdbqt files).  
 Prepare all the needing files for docking (grid parameter file, map files, docking 
Parameter files).  
 Run the docking for 100 runs.  
 Get the docking results.  
Grid Generation:  
The Grid box was given position (78, 58, and 70) and grid centre (10.76, 73.1, and 5.436) 
xyz coordinates. The binding site includes active site (HIS283, LYS232, TYR249, 
GLU245, ASP351, SER280) being ATP binding site.  
The Calculations of Auto grid and Autodock were performed on Linux operating system 
having system Properties (Intel(R) Pentium(R) D CPU 2.80GHz, 2.0 GB of RAM).  
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Figure 8 - Docked complex of TGFβ1 and Epicatechin Gallate 
6.7 Analysing Docking Results:  
 
Primarily the results of AutoDock can be analysed based on the best and lowest binding 
energies stored as a table in .dlg file (Docking Log file). This file can be opened using text 
editor and can be investigated for the inhibitory constant (Ki) and binding energy values.  
The interactions of the ligands with different amino acid residues of the receptor can found in 
detail by analysing the complex.pdb using  
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Ligand Scout.  
The following steps are followed-  
 Launch ligand Scout and open the complex.pdb  
 Double click on the boxed region where the ligand is highlighted.  
 Complex will be zoomed in to the interactive ligand-receptor region.  
 Now go to pharmacophore menu and select normalized pharmacophore.  
 The interactive amino acids of receptor with ligand are obtained.  
 
Figure 9 - Interacting amino acids with Epicatechin Gallate . 
Ligplot  
 Open complex file 
 Change ligand ATOM to HETATM 
 Carbon,nitrogen,oxygen, hydrogen  numbering 
 Replace numbering 1 2 3 with 5001 ,5002 like this 
 Replace UNK with DRG 
 Remove the data of docking in the complex file after receptor data 
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 Check the alignment with receptor alignment in the file 
 Save the file in pdb format 
 Open command promt 
 Cd ligplot 
 Ligplot filename.pdb DRG1 DRG1 
 Open the  .ps file  in post script viewer for atomic interactions 
 
 
Figure 10 - Atomic interactions of TGFβ1 with Epicatechin Gallate 
 
6.8 Structural variation of Epicatechin Gallate in designing new inhibitor 
for better binding 
 Bioisosteric substitution the process of starting with an initial active compound and 
replacing functional groups with other groups that have similar biological properties. 
Ex - Monovalent groups   H F Cl Br I OH SH NH2 PH2 CH3 SCH3 [48] 
 Variation in substituents is a method of generating many similar compounds even 
though the rules of bioisosteric replacement may not be followed [49] 
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 An extension of the parent structure is usually carried out by adding functional groups 
in locations where there were none in the parent 
 Extension  and contractions of both chains and rings are another valuable set of 
experiments [50] 
 Replacement of OH group with CH3 for interaction with LYS 337A 
 Replacement of OH group with CH3  for interaction with VAL219A , LEU260A 
SER280A 
  Replacement of OH group with CH3 for interaction with ILE211A 
 
Figure 11- Structural variations of Epicatechin Gallate  
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6.9 Pre ADMET Studies:  
The success of a drug depend on its ADME (Absorption, Distribution, Metabolism and 
Elimination) characters in the body. The early stage prediction of ADME of a new ligand 
reduces the probability of its failure at the drug development stage. Thus, these studies help 
in the Insilico analysis of not only ADME prediction but Molecular descriptors calculation, 
Drug likeness prediction, Drug toxicity prediction. The steps involved in Pre ADMET studies 
are as follows-  
 Open Pre ADMET server (http://preadmet.bmdrc.org/)  
 Register and login to the server  
 Prepare the .mol file of the ligands for analysis  
 Analyze the Drug likeness, ADME and Toxicity of the ligand from different tabs 
available in the login.  
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Figure 12 - Pre ADMET server home page 
6.10 MOLECULAR DYNAMICS SIMULATION by CHARMm: 
The molecular dynamics of the protein–inhibitor complex provides understanding to the 
flexibility associated with ligand conformational change, and thus provides an insight into 
molecular basis for inhibition. All of the simulations were carried out using the CHARMm 
package with an identical protocol [51]. The best orientation obtained out of docking of 
protein-ligand complex was used for simulation. We performed simulation for ligands 
SB505124 and S1and their respective binding with TGF-β. Here we separated the ligands 
from protein in order to prepare protein and ligand topology file separately. We used 
CHARMm force filed to generate topology file for protein. . The protein was solvated in a 
orthorhombic box with edges 1 nm in length using the explicit solvent–simple point charge 
model, which generated the water box. The next step followed the 2000 steps of steepest 
descent minimization and position restrained dynamics to distribute water molecule 
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throughout in 1000 ps. The next step of minimization followed conjugate gradient of 20000 
steps. The simulation was carried out at 300k of constant temperature and pressure of 500000 
steps for 1ns. Once the system was equilibrated with desired temperature and pressure the 
final step was to release the position restrains and run production of 125000 steps for 1ns for 
data collection. 
7. RESULT AND DISCUSSION 
7.1 Results of existing inhibitors docking:  
 
 
Figure 13 - Docked complex of TGFβR1 and Epicatechin Gallate. 
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Drug bank is the source of newly synthesized molecules with unknown activity. We have 
downloaded a group of small inhibitors from drug bank and selected few from literature for 
docking with TGFβR1. The results are tabulated below- 
 
INHIBITOR BINDING ENERGY (-VE) KI(µM) 
CID_447966 7.74 2.11 
CID_11676119 9.40 0.112 
CID_11599374 8.12 0.0112 
CID_23507473 8.68 0.434 
CID_49788486 8.74 0.390 
CID_25138294 8.19 0.996 
CID_23002763 4.50 501.8 
SB-431542 8.53 0.402 
SB505124 9.18 0.186 
EW7204 9.19 0.183 
CID_107905(Epicatechin 
Gallate) 
9.44 0.237 
CID_65064(EGCG) 9.04 0.120 
SM16 9.17 0.190 
SD208 8.0 1.37 
LY5504 8.76 0.382 
LY580276 7.55 2.93 
Table.1 Docking results of 16 Drug bank molecules with  TGFβR1 
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The Ligands and the receptors were retrieved and minimized as a preparatory step for 
Docking. Molecular Docking is performed using AutoDock 4. The TGFβR1 receptor is 
docked with the Epicatechin Gallate ligand which gave a good binding energy -9.44 
k.cal/mol. These results are compared with a standard SB505124 which gave a binding 
energy of -9.18 k.cal/mol, but Epicatechin Gallate cannot be used for severe scar hence 
further investigation is required to find out the effective inhibitor. 
7.2 Results of newly designed inhibitors docking: 
INHIBITOR BINDING ENERGY (-VE) KI(µM) 
S1 10.47 0.021 
S2 10.16 0.035 
S3 9.83 0.062 
S4 9.98 0.048 
S5 10.48 0.020 
Table.2 Docking results of 5 newly designed inhibitors with TGFβR1 
 
Newly designed inhibitor s5 and s1 showed better binding energy than existing inhibitor 
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7.3 Amino acids interactions with the inhibitors 
 
Figure 14 - Inhibitor Epicatechin Gallate interacting with amino acids from ligand 
scout and ligplot. 
 
 
Figure 15 - Interactions of S5 inhibitor with TGFβR1 amino acids (a), Atomic 
interactions with Amino acids (b). 
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Figure 16 - Interactions of s1 inhibitor with TGFβR1 amino acids (a), Atomic 
interactions with Amino acids (b). 
 
Figure 15 & 16 clearly shows many hydrophobic interactions hence giving better binding 
energy. 
7.4 PreADMET Results:  
Based on the binding energy of the existing inhibitors and newly designed inhibitors with 
TGFβR1 and the Ki value of the best conformation, are selected for PreADMET studies to 
know their Molecular descriptions, Drug Likeness, ADME data, Toxicity. Out of five newly 
designed inhibitors only  s1  qualified as drug. The results are tabulated as follows- 
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Table 3- Preadmet results of newly designed inhibitors 
 
S1 is found non toxic and qualified all the rule having good skin permeability ,hence can be 
used  as effective drug but further its stability has to be verified with molecular  dynamic 
simulation studies. 
7.5 Molecular dynamic simulation 
 
In Molecular Dynamic Simulation, energy calculation plays a vital role to determine the 
stability of the complex during simulation. Variation in kinetic energy, total energy 
components and potential energy verses time in MD Simulation are shown in Figure-17 and 
18 for Epicatechin Gallate, S1 respectively. From the plots it is clear that the kinetic energy 
and potential energy components fluctuate in equal and opposite direction. For the stability of 
the system, conservation of energy should be maintained. The figures show that conservation 
of energy is satisfied during MD Simulation, which indicates that the complexes during 
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simulation are quiet stable. Graph of all the two complexes shows that the kinetic energy is 
highest and the potential energy is lowest and this condition is required for a stable system. 
 
 
Figure 17- Energy diagram of ECG complex 
The energy diagram of the ECG and TGFβR1 complex is shown here. It shows that the 
kinetic energy of the system is maximum and it is about 5000 KJmol
-1
. Potential energy is 
minimum and it is of -20000 KJmol
-1
. Total energy is -17000 KJmol
-1
 and the value is in 
between K.E and P.E. the system is in stable condition since potential energy is negative and 
least among all the energy value. And also conservation of energy is followed here. So, ECG 
is showing its stability during the course of molecular dynamic simulation. 
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Figure 18 - Energy diagram of S1complex 
 
The energy diagram of the S1 is shown here. It shows that the kinetic energy of the system is 
maximum and it is about 20000 KJmol-1. Potential energy is minimum and it is of -80000 
KJmol-1. Total energy is -60000 KJmol-1 and the value is in between K.E and P.E. the 
system is in stable condition since potential energy is negative and least among all the energy 
value. And also conservation of energy is followed here. So S1 is showing its stability during 
the course of molecular dynamic simulation 
RMSD  
RMSD (Root Mean Square Deviation) is used to measure the conformational stability of a 
complex during simulation. The RMSD of the backbone atoms of the protein from the 
starting structure over the course of simulation may be used to measure the conformational 
stability of a protein during that simulation. The RMSD of the complex versus time plot are 
shown in the following figures. The dynamic behaviour and structural change of the receptor 
was evaluated by calculating the RMSD value. ECG Complex fluctuates between the RMSD 
values of 0.25Å-0.50Å as shown in figure19, whereas S1 complex shows less fluctuation 
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RMSD value between 0.25Å to 0.27Å as shown in figure 20. All the complexes showed 
RMSD value in the highly acceptable range, with very less fluctuation. The outcome results 
indicate that the complexes formed by these ligands and receptors are quiet stable. 
 
 
Figure 19 - RMSD plot cof ECG complex 
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Figure 20 – RMSD plot of S1 complex 
 
MD simulations were performed to determine the stability of the protein-ligand complex. The 
total energy drift during entire production simulation of the second 1000 ps, the drift was 
−17372,-62957 (kcal/mol) for respective protein ligand complex. The lower the value for 
total energy more stable is the complex and higher is the binding affinity. Hence S1 having 
less energy valve is showing better binding affinity than ECG. Both the complex were stable 
at body temperature of 300k To monitor the stability of  the RMSD values of all the atoms of 
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protein-ligand complex to relative to the starting structure versus simulation time were 
measured. As can be seen from the plot, the RMSD fluctuations are similar in both the  
systems around 0.30 Å. Both the complexes were likely to reach equilibrium at 1ns. Further 
ahead the drug positional rmsd was used to determine the mobility of the drug in protein 
binding pocket. The ligands exhibited root mean square deviation of 0.50, 0.25 Å 
respectively  as shown in figure 19 &20. The lower deviation exhibit the ligand to be closer 
to protein binding site forming stable complex. Thus from the above results the conclusion 
can be drawn is that the S1 complex was comparatively more stable as compared to parent 
ECG complex.  
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8. CONCLUSION 
By analysing the Molecular Docking results i.e., binding energies of all the molecules   
Epicatechin Gallate possesses promising inhibitory activity against TGFβ1 receptor. But this 
inhibitor won’t be effective in case of severe scar hence to further strengthen the binding 
affinity; five new ligands were designed by structural modifications of Epicatechin Gallate. 
Out of five derivatives of Epicatechin Gallate, S1 & S5 showed better binding than existing 
inhibitors. Further the Pre ADMET results showed a positive outcome with S1 compound 
showing good dermal absorption, drug likeness and non-carcinogenicity. Its stability was 
validated by MD Simulation at 1ns, RMSD, and Energy graphs showed high stability of the 
ligand-receptor complex at the time of Molecular Dynamic Simulation. Combining the above 
outcomes, we can conclude that the S1 as effective inhibitor of TGF-β pathway can be used 
in the superficial severe scar treatment. However, the results need further confirmation by 
wet lab experiments followed by clinical trials before it’s translation into clinics. 
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